Usmani

Dr Usmani discusses the FDA approval of cilta-cel for relapsed/refractory multiple myeloma patients who have had at least 1 prior line of therapy. Topics include comparing CAR-T cell therapy benefits to standard care regimens, impacts on earlier treatment settings, patient accessibility, a comparative study of cilta-cel vs. standard care regimens, FDA advisory committee meeting insights, safety, and the role of cilta-cel in multiple myeloma treatment.

Dr. Usmani discusses the use of bispecific antibodies in treating relapsed/refractory multiple myeloma, emphasizing their integration into current management strategies. Topics include adverse effects, supportive care, patient selection, dosing considerations, toxicity management, and ongoing research for improved treatment outcomes.